Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by Evercore ISI

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) was downgraded by Evercore ISI from an "outperform" rating to an "inline" rating in a report released on Thursday,Briefing.com Automated Import reports. They presently have a $50.00 price objective on the biotechnology company's stock. Evercore ISI's target price would suggest a potential upside of 36.17% from the stock's current price.

Several other equities analysts have also recently commented on SRPT. The Goldman Sachs Group reduced their target price on Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating for the company in a research report on Wednesday. Wells Fargo & Company initiated coverage on shares of Sarepta Therapeutics in a research report on Friday, April 11th. They issued an "overweight" rating and a $115.00 price objective on the stock. Royal Bank of Canada dropped their target price on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating for the company in a research report on Wednesday. HC Wainwright decreased their price target on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating on the stock in a report on Wednesday. Finally, Morgan Stanley dropped their price objective on shares of Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating for the company in a report on Wednesday. Six investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $131.87.

Sarepta Therapeutics Trading Down 21.5 %

NASDAQ:SRPT opened at $36.72 on Thursday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics has a 1 year low of $36.59 and a 1 year high of $173.25. The company has a market cap of $3.61 billion, a P/E ratio of 29.38 and a beta of 0.85. The stock's fifty day moving average price is $69.47 and its two-hundred day moving average price is $102.12.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same quarter last year, the business posted $0.73 earnings per share. Sarepta Therapeutics's revenue was up 80.2% compared to the same quarter last year. As a group, analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Buying and Selling

In related news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares of the company's stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.70% of the stock is currently owned by insiders.

Institutional Trading of Sarepta Therapeutics

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Sarepta Therapeutics by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock valued at $1,104,701,000 after acquiring an additional 117,904 shares in the last quarter. Capital International Investors boosted its holdings in shares of Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 11.1% during the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after buying an additional 285,100 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in shares of Sarepta Therapeutics by 0.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company's stock worth $237,901,000 after buying an additional 10,343 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company's stock worth $207,538,000 after acquiring an additional 9,999 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.